---
title: "COMPASS Pathways plc (CMPS.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/CMPS.US/overview.md"
symbol: "CMPS.US"
name: "COMPASS Pathways plc"
parent: "https://longbridge.com/zh-HK/quote/CMPS.US.md"
datetime: "2026-04-15T23:14:58.598Z"
locales:
  - [en](https://longbridge.com/en/quote/CMPS.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CMPS.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CMPS.US/overview.md)
---

# COMPASS Pathways plc (CMPS.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | 生物技術 |
| 交易所 | US Market |
| 地址 | 33 Broadwick Street, London, Greater London, United Kingdom |
| 官網 | [compasspathways.com](https://compasspathways.com) |

## 公司簡介

COMPASS Pathways plc 是一家生物技術公司，專注于英國和美國的心理健康。該公司開發了 COMP360，一種用于治療耐藥性抑鬱症的迷幻蘑菇治療，目前正在進行第三階段臨床試驗；同時也在進行第二階段臨床試驗，以治療創傷后應激障礙和神經性厭食症。該公司曾名為 COMPASS Rx Limited，並于 2020 年 8 月更名為 COMPASS Pathways plc。公司成立于 2020 年，總部位于英國倫敦

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Kabir Kumar Nath | CEO & Director |
| Gino Santini | Independent Chairman |
| Teri Loxam | Chief Financial Officer |
| Guy Goodwin | Chief Medical Officer |
| Stephen D. Schultz | Senior Vice President of Investor Relations |
| Lars Christian Wilde | Senior Advisor |
| Annalisa Lisa Mary Jenkins | Independent Non-Executive Director |
| Daphne Karydas | Independent Director |
| David York Norton | Independent Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| RTW Investments, LP | 6.79% | 2025-12-31 |
| Deep Track Capital, LP | 5.69% | 2025-12-31 |
| AtaiBeckley Inc. | 3.70% | 2026-01-21 |
| GMT Capital Corp. | 2.21% | 2025-12-31 |
| The Toronto-Dominion Bank | 1.96% | 2025-12-31 |
| ARK Investment Management LLC | 1.67% | 2025-12-31 |
| George Jay Goldsmith | 1.59% | 2025-03-31 |
| UBS Asset Management AG | 1.58% | 2025-12-31 |
| Ekaterina Malievskaia | 1.57% | 2025-03-31 |
| Two Sigma Investments, LP | 1.28% | 2025-12-31 |


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**